Skip to main content
. 2009 Jul 10;32(10):1783–1788. doi: 10.2337/dc09-0585

Figure 1.

Figure 1

BMI 12 months before and 6 and 12 months after treatment with insulin (red), placebo (blue), or repaglinide (black) in 61 subjects with CFRD FH− (A) and 20 subjects with IGT (B). Data are means ± SEM. P values are for study year (0–12 months) compared with previous year (−12 to 0 months) within each group.